Ablation of Tak1 in osteoclast progenitor leads to defects in skeletal growth and bone remodeling in mice

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Qi, Bing ^a   Cong, Qian ^b   Li, Ping ^b   Ma, Gang ^b   Guo, Xizhi ^b   Yeh, James ^b   Xie, Min ^c   Schneider, Michael D ^d   Liu, Huijuan ^b   Li, Baojie ^b  

^a TAISHAN MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; RECEPTOR REGULATED SMAD PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL; ARTICULAR CARTILAGE; BONE DEVELOPMENT; BONE REMODELING; CELL CULTURE; CELL DIFFERENTIATION; COCULTURE; CYTOLOGY; DEFICIENCY; GENETICS; GROWTH, DEVELOPMENT AND AGING; KNOCKOUT MOUSE; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; OSTEOCLAST; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKULL;

ANIMALS; BONE REMODELING; CARTILAGE, ARTICULAR; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; MALE; MAP KINASE KINASE KINASES; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; NF-KAPPA B; OSTEOCLASTS; OSTEOGENESIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENOTYPE; SIGNAL TRANSDUCTION; SKULL; SMAD PROTEINS, RECEPTOR-REGULATED; TRANSCRIPTION FACTORS;

EID: 84927764937     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07158     Document Type: Article

References (50)

1. Rachner, T. D., Khosla, S. & Hofbauer, L. C. Osteoporosis: now and the future. Lancet 377, 1276-1287 (2011).
2. Manolagas, S. C. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 31, 266-300 (2010).
3. Baron, R. Osteoporosis in 2011: Osteoporosis therapy - dawn of the post-bisphosphonate era. Nat Rev Endocrinol 8, 76-78 (2012).
4. Karsenty, G., Kronenberg, H. M. & Settembre, C. Genetic control of bone formation. Annu Rev Cell Dev Biol 25, 629-648 (2009).
5. Bruzzaniti, A. & Baron, R. Molecular regulation of osteoclast activity. Rev Endocr Metab Disord 7, 123-139 (2006).
6. Boyce, B. F., Rosenberg, E., de Papp, A. E. & Duong le, T. The osteoclast, bone remodelling and treatment of metabolic bone disease. Eur J Clin Invest 42, 1332-1341 (2012).
7. Feng, X. & McDonald, J. M. Disorders of bone remodeling. Annu Rev Pathol 6, 121-145 (2011).
8. Edwards, J. R. & Mundy, G. R. Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol 7, 235-243 (2011).
9. Lacey, D. L. et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11, 401-419 (2012).
10. Karsenty, G. Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet 9, 183-196 (2008).
11. Tondravi, M. M. et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 386, 81-84 (1997).
12. Kitaura, H. et al. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 115, 3418-3427 (2005).
13. Srivastava, S. et al. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J Clin Invest 102, 1850-1859 (1998).
14. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
15. Wada, T., Nakashima, T., Hiroshi, N. & Penninger, J. M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12, 17-25 (2006).
16. Wang, C. et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346-351 (2001).
17. Grigoriadis, A. E. et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443-448 (1994).
18. Weilbaecher, K. N. et al. Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi/mi) mice. Mol Cell 8, 749-758 (2001).
19. Ishitani, T. et al. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature 399, 798-802 (1999).
20. A, B. TGF-βinduces fibronectin synthesis through a c-Jun.pdf. EMBO J 18, 1345-56 (1999).
21. Mu, Y., Gudey, S. K. & Landstrom, M. Non-Smad signaling pathways. Cell Tissue Res 347, 11-20 (2012).
22. Wu, M. et al. Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res 72, 2833-2843 (2012).
23. Singh, A. et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148, 639-650 (2012).
24. Yang, Y. et al. A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell Biol 31, 2774-2786 (2011).
25. Jadrich, J. L., O'Connor, M. B. & Coucouvanis, E. The TGF beta activated kinase TAK1 regulates vascular development in vivo. Development 133, 1529-1541 (2006).
26. Ajibade, A. A., Wang, H. Y. & Wang, R. F. Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol 34, 307-316 (2013).
27. Tang, M. TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice. J Exp Med 205, 1611-9 (2008).
28. Pera, T., Sami, R., Zaagsma, J. & Meurs, H. TAK1 plays a major role in growth factor-induced phenotypic modulation of airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 301, L822-828 (2011).
29. Inokuchi, S. et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci U S A 107, 844-849 (2010).
30. Xie, M. et al. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A 103, 17378-17383 (2006).
31. Zhang, D. et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 6, 556-563 (2000).
32. Lamothe, B., Lai, Y., Xie, M., Schneider, M. D. & Darnay, B. G. TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis. Mol Cell Biol 33, 582-595 (2013).
33. Gingery, A. et al. TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res 314, 2725-2738 (2008).
34. Ajibade, A. A. et al. TAK1 negatively regulates NF-kappaB and p38 MAP kinase activation in Gr-1+CD11b+ neutrophils. Immunity 36, 43-54 (2012).
35. Winkeler, C. L., Kladney, R. D., Maggi, L. B., Jr. & Weber, J. D. Cathepsin K-Cre causes unexpected germline deletion of genes in mice. PloS One 7, e42005 (2012).
36. Ma, G. et al. Atypical Atm-p53 genetic interaction in osteogenesis is mediated by Smad1 signaling. J Mol Cell Biol 4, 118-120 (2012).
37. Kua, H. Y. et al. c-Abl promotes osteoblast expansion by differentially regulating canonical and non-canonical BMP pathways and p16INK4a expression. Nat Cell Biol 14, 727-737 (2012).
38. Li, B. et al. Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat Genet 24, 304-308 (2000).
39. Wang, X. et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol 172, 115-125 (2006).
40. Broege, A. et al. Bone morphogenetic proteins signal via SMAD and mitogen-activated protein (MAP) kinase pathways at distinct times during osteoclastogenesis. J Biol Chem 288, 37230-37240 (2013).
41. Dougall, W. C. et al. RANK is essential for osteoclast and lymph node development. Genes Dev 13, 2412-2424 (1999).
42. Gunnell, L. M. et al. TAK1 regulates cartilage and joint development via the MAPK and BMP signaling pathways. J Bone Miner Res 25, 1784-1797 (2010).
43. Shim, J. H. et al. TAK1 is an essential regulator of BMP signalling in cartilage. EMBO J 28, 2028-2041 (2009).
44. Okamoto, M. et al. Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice. J Bone Miner Res 26, 2511-2522 (2011).
45. Iwata, J. et al. Modulation of noncanonical TGF-beta signaling prevents cleft palate in Tgfbr2 mutant mice. J Clin Invest 122, 873-885 (2012).
46. Gao, L. et al. TAK1 regulates SOX9 expression in chondrocytes and is essential for postnatal development of the growth plate and articular cartilages. J Cell Sci 126, 5704-5713 (2013).
47. Greenblatt, M. B. et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest 120, 2457-2473 (2010).
48. Hong, S. et al. Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2. Nat Immunol 8, 504-513 (2007).
49. Hoffmann, A. et al. Transforming growth factor-beta-activated kinase-1 (TAK1), a MAP3K, interacts with Smad proteins and interferes with osteogenesis in murine mesenchymal progenitors. J Biol Chem 280, 27271-27283 (2005).
50. Arsura, M. et al. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene 22, 412-425 (2003).